Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database.

Yuqin Wang | Lele Chang | Haixin He | Xuemei Zhang | Jing Liu | Lele Zang | Li Li | Tongyu Liu | Qin Xu
Discover oncology | 2025

The COVID-19 pandemic has significantly impacted cancer diagnosis, treatment, and prognosis; however, its effects on ovarian cancer remain unclear.

Pubmed ID: 40244485

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: Innovative Medicine Subject of Fujian Provincial Health Commission,
    Id: 2022CXA029
  • Agency: Fujian Clinical Research Center for Radiation and Therapy of Digestive, Respiratory and Genitourinary Malignancies,
    Id: 2021Y2014
  • Agency: Fujian Province Science and Technology Innovation Joint Fund Project,
    Id: 2023Y9449
  • Agency: Natural Science Foundation of Fujian Province,
    Id: 2023J011273
  • Agency: Fujian Cancer Hospital High-Level Talent Training Program,
    Id: 2024YNG09

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Surveillance Epidemiology and End Results (tool)

RRID:SCR_006902

SEER collects cancer incidence data from population-based cancer registries covering approximately 47.9 percent of the U.S. population. The SEER registries collect data on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment, and they follow up with patients for vital status.There are two data products available: SEER Research and SEER Research Plus. This was motivated because of concerns about the increasing risk of re-identifiability of individuals. The Research Plus databases require more rigorous process for access that includes user authentication through Institutional Account or multiple-step request process for Non-Institutional users.

View all literature mentions

SEER (tool)

RRID:SCR_015499

Sequence element enrichment analysis tool to perform pan-genome-wide association studies in bacteria.

View all literature mentions